Suppr超能文献

胰腺导管腺癌胰十二指肠切除术后化疗完成率及总生存期与术后并发症的相关性

Association of chemotherapy completion rates and overall survival with postoperative complications after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

作者信息

Kollbeck Sophie L G, Hansen Carsten P, Dencker Emilie E, Krohn Paul S, Storkholm Jan H, Burgdorf Stefan K, Millarch Andreas S, Piper Thomas B, Hillingsø Jens G, Sillesen Martin

机构信息

Department of Organ Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 København Ø, Denmark; Center for Surgical Translation and Artificial Intelligence Research (CSTAR), Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 København Ø, Denmark.

Department of Organ Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 København Ø, Denmark.

出版信息

HPB (Oxford). 2025 Feb;27(2):222-231. doi: 10.1016/j.hpb.2024.11.002. Epub 2024 Nov 9.

Abstract

INTRODUCTION

Despite the benefits of surgical resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDAC), over 30 % of patients fail to complete adjuvant oncological treatment. Whether postoperative complications affect chemotherapy completion rates and overall survival remains uncertain. We hypothesized that postoperative complications would be associated with chemotherapy delays, omission, and reduced overall survival (OS).

METHODS

This was a retrospective analysis of patients undergoing pancreaticoduodenectomy for PDAC from 2008 to 2022 to assess whether serious surgical complications, defined as Clavien Dindo Grade 3b or higher, were associated with the omission or delay of adjuvant oncologic treatment as well as OS.

RESULTS

A total of 920 patients were available for analysis. Pancreatic and bile leakage were associated with risk of chemotherapy omission (OR 1.97 [CI 95 % 1.25-3.12], p = 0.004 and OR 1.96 [CI 95 % 1.04-3.67], p = 0.032, respectively). No delay of adjuvant chemotherapy >90 days nor change in OS was found.

CONCLUSION

Major surgical complications influence the likelihood of omitting adjuvant chemotherapy but not delaying it > 90 days. Patients with pancreatic or bile leakage were at greater risk of not completing planned chemotherapy but had the same OS.

摘要

引言

尽管手术切除和辅助化疗对胰腺导管腺癌(PDAC)有益,但超过30%的患者未能完成辅助肿瘤治疗。术后并发症是否会影响化疗完成率和总生存期仍不确定。我们假设术后并发症会与化疗延迟、遗漏以及总生存期(OS)缩短相关。

方法

这是一项对2008年至2022年因PDAC接受胰十二指肠切除术患者的回顾性分析,以评估严重手术并发症(定义为Clavien Dindo 3b级或更高等级)是否与辅助肿瘤治疗的遗漏或延迟以及总生存期相关。

结果

共有920例患者可供分析。胰漏和胆漏与化疗遗漏风险相关(分别为OR 1.97 [95%CI 1.25 - 3.12],p = 0.004和OR 1.96 [95%CI 1.04 - 3.67],p = 0.032)。未发现辅助化疗延迟超过90天,总生存期也无变化。

结论

主要手术并发症影响辅助化疗遗漏的可能性,但不影响延迟超过90天。发生胰漏或胆漏的患者未完成计划化疗的风险更高,但总生存期相同。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验